8-K: LifeMD Divests WorkSimpli, Sharpens Virtual Care Focus

LifeMD, Inc. announced the sale of its majority ownership interest in WorkSimpli Software LLC for an enterprise value of approximately $65 million, sharpening its focus on virtual healthcare and pharmacy.

Summary

• LifeMD, Inc. sold its majority ownership interest (80% of outstanding units) in WorkSimpli Software LLC to a buyer group led by WorkSimpli founder and CEO Sean Fitzpatrick.
• The transaction values WorkSimpli at an enterprise value of approximately $65.0 million.
• LifeMD received $22.0 million in cash at closing, representing 91.6% of the $24.0 million base purchase price attributable to the 80% interest sold.
• The sellers are eligible to receive up to an additional $28.0 million in cash upon WorkSimpli achieving defined growth and operational targets over the next three years.
• The transaction closed simultaneously with the execution of the Stock Purchase Agreement on November 4, 2025.
• LifeMD expects to utilize its existing Net Operating Loss carryforwards (NOLs) to offset the majority of the capital gains generated from the sale.
• LifeMD's total investment in WorkSimpli since June 2018 was approximately $1.25 million, holding 73.3% ownership immediately prior to the closing.

Sentiment

Score: 8

Explanation: The divestiture is a highly strategic move, strengthening LifeMD's balance sheet with a significant cash inflow and allowing for a focused pursuit of high-growth virtual healthcare and pharmacy markets. The potential for substantial future performance-based payments adds to the positive financial outlook, and the use of NOLs is a favorable tax outcome. This positions LifeMD for accelerated growth and enhanced shareholder value.

Positives

• Strengthens LifeMD's balance sheet with a $22.0 million cash payment at closing.
• Positions LifeMD as a pure-play virtual care and pharmacy platform, allowing for sharpened strategic focus.
• Enables LifeMD to accelerate growth across core business lines and expand into new clinical verticals.
• Provides potential for up to an additional $28.0 million in cash based on WorkSimpli's future performance targets.
• Utilizes existing Net Operating Loss carryforwards (NOLs) to offset the majority of capital gains from the sale.

Negatives

• Divestiture means LifeMD will no longer benefit from WorkSimpli's positive cash flow contributions.

Risks

• Forward-looking statements regarding future plans and financial outcomes are subject to numerous assumptions, risks, and uncertainties, and actual results may differ materially.
• Achievement of the up to $28.0 million in future performance targets is contingent on WorkSimpli meeting specific Company Adjusted EBITDA and subscription targets, which are inherently uncertain.
• The Purchaser's operation of WorkSimpli's business following the closing may impact the achievement of the performance and activation amounts.
• Potential for Data Breach prior to Closing, including events underlying the 2022 and/or 2024 common point of payment notifications, to the extent any Data Breach in fact occurred.
• Risk of misclassification by the Company prior to Closing of any Business Employees as exempt under the Fair Labor Standards Act of 1938.
• Risk of non-compliance by the Company prior to Closing with the requirements of the Puerto Rico Tax Decree and Act 20-2012.
• Potential for Closing Date Indebtedness and/or Company Transaction Expenses not included in the adjustment to the Base Purchase Price.

Future Outlook

LifeMD will concentrate its resources on expanding its virtual care and pharmacy offerings, with a continued focus on weight management, women's health, behavioral health, urgent care, and primary care. The company plans to broaden its platform into more complex, longitudinal cardiometabolic care offerings beginning in the first half of 2026. Additionally, LifeMD will continue to scale its Rex MD product portfolio, which focuses on asynchronous men's healthcare, e-pharmacy solutions, and men's hormonal health.

Management Comments

• Justin Schreiber, Chairman and CEO of LifeMD: "By divesting our majority stake in WorkSimpli, we are sharpening our focus on what we do best: building and scaling one of the most comprehensive virtual care technology platforms in the industry. This strategic move strengthens our balance sheet and positions LifeMD to accelerate growth across our core business lines, expand into new clinical verticals, and deliver even greater value to our patients, providers, and shareholders."
• Justin Schreiber, Chairman and CEO of LifeMD: "I want to congratulate WorkSimpli founder and CEO Sean Fitzpatrick and his team for their dedication and hard work in building such an exceptional business. Sean is an incredible entrepreneur, operator and marketer, and I have no doubt that WorkSimpli will continue to thrive as an independent, private company."
• Stefan Galluppi, Co-Founder and Chief Innovation Officer of LifeMD: "They've built an incredible business with strong leadership, a culture of innovation, and a product suite that continues to deliver value to users. I have complete confidence in Sean's ability to continue scaling the business to even greater heights, and I look forward to watching WorkSimpli thrive as it enters this next chapter."
• Sean Fitzpatrick, CEO of WorkSimpli: "Independence gives us the flexibility to invest in our people and products and continue delivering value to our customers at scale. We're grateful to LifeMD for their vision and partnership in helping us reach this milestone."

Industry Context

This divestiture aligns with a broader industry trend where companies streamline their portfolios to focus on core, high-growth segments. By shedding WorkSimpli, a SaaS productivity tools provider, LifeMD is strategically positioning itself as a pure-play virtual healthcare and pharmacy company. This move allows LifeMD to allocate more capital and management attention to the rapidly expanding and competitive virtual care market, potentially enhancing its ability to innovate and scale within specialized healthcare verticals like weight management, women's health, and cardiometabolic care. This focus could improve its competitive standing against other specialized telehealth providers.

Legal Proceedings

• The filing mentions potential indemnification claims related to past Data Breaches (including 2022 and/or 2024 common point of payment notifications), misclassification of Business Employees under the Fair Labor Standards Act of 1938, and non-compliance with the Puerto Rico Tax Decree and Act 20-2012, but does not announce new legal proceedings.

Related Party Transactions

• The transaction involves LifeMD (a seller) and WorkSimpli Software LLC (the company being sold), in which LifeMD held a majority interest. The buyer group was led by WorkSimpli founder and CEO Sean Fitzpatrick.

Stakeholder Impact

• Shareholders (LifeMD): Expected to benefit from a strengthened balance sheet, a clearer strategic focus on high-growth virtual care, and potential future earn-out payments.
• Patients and Providers (LifeMD): Anticipated to receive greater value through expanded and more focused virtual care and pharmacy offerings.
• Employees (WorkSimpli): The WorkSimpli team will continue under new ownership, led by its founder and CEO, Sean Fitzpatrick, suggesting continuity for its workforce.
• Employees (LifeMD): The strategic focus on core healthcare businesses could lead to new growth opportunities and resource allocation within LifeMD.

Next Steps

• LifeMD will concentrate resources on expanding its virtual care and pharmacy offerings, including weight management, women's health, behavioral health, urgent care, and primary care.
• LifeMD plans to broaden its platform into more complex, longitudinal cardiometabolic care offerings beginning in the first half of 2026.
• LifeMD will continue to scale its Rex MD product portfolio, focusing on asynchronous men's healthcare, e-pharmacy solutions, and men's hormonal health.
• WorkSimpli is expected to achieve defined growth and operational targets over the next three years to trigger additional performance-based payments to the sellers.
• WorkSimpli may market for sale the assets of ResumeBuild during the Performance Period or Activation Period.
• The Purchaser and Company will cause Payment Processors to enter into new agreements with the Company.
• LifeMD will promptly deliver any payments attributable to the Company processed by Payment Processors to the Company within 30 business days after the Closing Date.

Key Dates

Recommendation

The divestiture of a non-core asset for a substantial valuation, coupled with a clear strategic focus on high-growth virtual healthcare and pharmacy, significantly strengthens LifeMD's financial position and future growth prospects. The potential for significant earn-out payments further enhances the deal's attractiveness, and the use of NOLs to offset capital gains is a positive financial management aspect. This strategic realignment positions LifeMD for accelerated growth and increased shareholder value in its core market.

Keywords

LifeMD, LFMD, WorkSimpli, Divestiture, Virtual Care, Telemedicine, Pharmacy, Healthcare, SaaS, Strategic Sale, M&A, Nasdaq, SEC Filing, 8-K, Net Operating Loss, NOLs, Enterprise Value